Sort   by:  
 Page size 
UnknownA Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Not available
S-EPMC10010313 | biostudies-literature
UnknownPhase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Not available
S-EPMC8574211 | biostudies-literature
UnknownOpen-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
Not available
S-EPMC11295983 | biostudies-literature
UnknownP882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
Not available
S-EPMC10431058 | biostudies-literature
UnknownPomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Not available
S-EPMC7685974 | biostudies-literature
UnknownUmbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Not available
S-EPMC8148421 | biostudies-literature
UnknownThree-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Not available
S-EPMC9870225 | biostudies-literature
UnknownKTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Not available
S-EPMC7731441 | biostudies-literature
UnknownThe phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Not available
S-EPMC6284216 | biostudies-literature
UnknownIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Not available
S-EPMC7449872 | biostudies-literature
Sort   by:  
 Page size